Renata Medical Secures $25M for Pediatric Heart Stent Expansion
August 25, 2026, 9:38 am
Renata Medical, a Newport Beach med-tech firm, secured $25 million in Series D funding. ARCHIMED led the pivotal round. This capital accelerates U.S. commercialization of the Minima Stent System. It also targets international market expansion. The Minima Stent is a breakthrough for pediatric congenital heart disease. It is the first balloon-expandable growth stent. It specifically serves neonates, infants, and young children. FDA premarket approval came in 2024. CMS granted NTAP status in 2025. This investment furthers the company's mission. It aims to develop purpose-built cardiovascular devices for children. Existing investors also participated. The funding supports broader adoption and clinical evidence generation. It promises better outcomes for young heart patients.
Renata Medical announces a significant financial milestone. The company raised $25 million in Series D financing. This investment fuels critical expansion plans. It targets the U.S. and international markets. ARCHIMED, a dedicated healthcare investment firm, spearheaded the round. Existing investors also contributed to this capital infusion.
The funding primarily supports the Minima Stent System. This innovative device is revolutionizing pediatric cardiovascular care. It addresses a critical unmet need for children with congenital heart disease (CHD). Expansion of U.S. commercialization efforts remains a top priority. The company aims for broader adoption across specialized congenital heart programs.
International market entry is also on the horizon. Renata Medical seeks to bring its technology to more young patients globally. Furthermore, the capital will advance Renata Medical's broader pipeline. New pediatric-specific CHD technologies are in development. Continued clinical evidence generation is also a key focus. This ensures ongoing validation of the Minima Stent System’s effectiveness.
The Minima Stent System stands as a groundbreaking innovation. It is the first balloon-expandable growth stent. Its design is explicitly for neonates, infants, and young children. This contrasts sharply with adult devices often adapted for pediatric use. The stent addresses conditions like pulmonary artery stenosis. It also treats coarctation of the aorta.
Regulatory milestones underscore the Minima Stent System's impact. The U.S. Food and Drug Administration (FDA) granted premarket approval in August 2024. This marked a pivotal moment for pediatric cardiology. A year later, in August 2025, the Centers for Medicare & Medicaid Services (CMS) awarded Minima an NTAP designation. This New Technology Add-on Payment designation provides crucial reimbursement support for hospitals. It facilitates greater access to this advanced technology.
Market adoption of Minima has surpassed initial expectations. The stent launched commercially in 2024. Clinical demand has grown steadily since then. This rapid uptake validates the urgent need for pediatric-specific cardiovascular solutions. Physicians recognize its unique advantages for growing children.
Renata Medical was founded in 2019. Its mission focuses on improving care for children with CHD. The company recognized a longstanding challenge. Children with heart defects often received treatment with devices designed for adult anatomy. These devices frequently fail to accommodate growth. This leads to numerous repeat interventions throughout a child's life.
The Minima Stent System directly addresses this problem. Its growth-enabling design allows for expansion as a child grows. This unique feature can potentially reduce the frequency of repeat procedures. It offers a more durable, patient-centric solution. Renata Medical's approach is truly purpose-built.
Dustin Armer co-founded Renata Medical and serves as its CEO. His leadership drives the company’s commitment to pediatric innovation. The team focuses on creating, manufacturing, and selling technology tailored for children. This dedication distinguishes Renata Medical in the med-tech landscape. The company operates from Newport Beach, California. This location fosters a vibrant medical technology ecosystem.
ARCHIMED’s investment highlights the significant market opportunity. ARCHIMED manages approximately €9 billion. Its exclusive focus is healthcare investments. The firm identifies companies transforming patient care. Their participation validates Renata Medical's vision and progress. They recognize the profound impact Minima can have on young lives.
This funding round solidifies Renata Medical's position. It emerges as a leader in pediatric cardiovascular devices. The capital ensures robust growth and continued innovation. It enables the company to reach more children in need. Broader access to specialized care is now more attainable.
The future of pediatric heart care looks brighter. Companies like Renata Medical are driving this change. They develop technologies that grow with children. They reduce the burden of repeated surgeries. This leads to better long-term outcomes and improved quality of life. The $25 million investment marks a new chapter. It promises significant advancements for children with congenital heart disease.
Renata Medical announces a significant financial milestone. The company raised $25 million in Series D financing. This investment fuels critical expansion plans. It targets the U.S. and international markets. ARCHIMED, a dedicated healthcare investment firm, spearheaded the round. Existing investors also contributed to this capital infusion.
The funding primarily supports the Minima Stent System. This innovative device is revolutionizing pediatric cardiovascular care. It addresses a critical unmet need for children with congenital heart disease (CHD). Expansion of U.S. commercialization efforts remains a top priority. The company aims for broader adoption across specialized congenital heart programs.
International market entry is also on the horizon. Renata Medical seeks to bring its technology to more young patients globally. Furthermore, the capital will advance Renata Medical's broader pipeline. New pediatric-specific CHD technologies are in development. Continued clinical evidence generation is also a key focus. This ensures ongoing validation of the Minima Stent System’s effectiveness.
The Minima Stent System stands as a groundbreaking innovation. It is the first balloon-expandable growth stent. Its design is explicitly for neonates, infants, and young children. This contrasts sharply with adult devices often adapted for pediatric use. The stent addresses conditions like pulmonary artery stenosis. It also treats coarctation of the aorta.
Regulatory milestones underscore the Minima Stent System's impact. The U.S. Food and Drug Administration (FDA) granted premarket approval in August 2024. This marked a pivotal moment for pediatric cardiology. A year later, in August 2025, the Centers for Medicare & Medicaid Services (CMS) awarded Minima an NTAP designation. This New Technology Add-on Payment designation provides crucial reimbursement support for hospitals. It facilitates greater access to this advanced technology.
Market adoption of Minima has surpassed initial expectations. The stent launched commercially in 2024. Clinical demand has grown steadily since then. This rapid uptake validates the urgent need for pediatric-specific cardiovascular solutions. Physicians recognize its unique advantages for growing children.
Renata Medical was founded in 2019. Its mission focuses on improving care for children with CHD. The company recognized a longstanding challenge. Children with heart defects often received treatment with devices designed for adult anatomy. These devices frequently fail to accommodate growth. This leads to numerous repeat interventions throughout a child's life.
The Minima Stent System directly addresses this problem. Its growth-enabling design allows for expansion as a child grows. This unique feature can potentially reduce the frequency of repeat procedures. It offers a more durable, patient-centric solution. Renata Medical's approach is truly purpose-built.
Dustin Armer co-founded Renata Medical and serves as its CEO. His leadership drives the company’s commitment to pediatric innovation. The team focuses on creating, manufacturing, and selling technology tailored for children. This dedication distinguishes Renata Medical in the med-tech landscape. The company operates from Newport Beach, California. This location fosters a vibrant medical technology ecosystem.
ARCHIMED’s investment highlights the significant market opportunity. ARCHIMED manages approximately €9 billion. Its exclusive focus is healthcare investments. The firm identifies companies transforming patient care. Their participation validates Renata Medical's vision and progress. They recognize the profound impact Minima can have on young lives.
This funding round solidifies Renata Medical's position. It emerges as a leader in pediatric cardiovascular devices. The capital ensures robust growth and continued innovation. It enables the company to reach more children in need. Broader access to specialized care is now more attainable.
The future of pediatric heart care looks brighter. Companies like Renata Medical are driving this change. They develop technologies that grow with children. They reduce the burden of repeated surgeries. This leads to better long-term outcomes and improved quality of life. The $25 million investment marks a new chapter. It promises significant advancements for children with congenital heart disease.